KCTD17 and metabolic dysfunction-associated steatohepatitis: Our study further identified a strong correlation between KCTD17 expression and disease severity in both human patients and murine models of MASH, indicating that KCTD17 is not only a biomarker of fibrosis but also a potential driver of disease progression.